Following U.S. Stocks were among the “Top Gainers” during Friday’s trade: Midstates Petroleum Company, Inc. (NYSE:MPO), The Fresh Market, Inc. (NASDAQ:TFM), Catalyst Pharmaceutical Partners Inc. (CPRX), InspireMD, Inc. (NYSEMKT:NSPR)

Their insights are depicted underneath:

Midstates Petroleum Company, Inc. (NYSE:MPO)’s shares picked up 3.64%, and closed at $1.14.

According to BUSINESS WIRE, on March 2, Midstates Petroleum Corporation, Inc. (MPO), declared that the Corporation has postponed its fourth quarter 2014 earnings release and conference call, originally planned for Tuesday March 3 and Wednesday March 4, 2015, to allow for more time to finalize its year-end financial results. A press release will be forth coming about its rescheduled earnings date.

Midstates Petroleum Corporation, Inc. is an independent exploration and production corporation focused on the application of modern drilling and completion techniques in oil and liquids-rich basins in the onshore U.S. Midstates’ drilling and completion efforts are presently focused in the Mississippian Lime oil play in Oklahoma and Anadarko Basin in Texas and Oklahoma.

The Fresh Market, Inc. (NASDAQ:TFM) raised 3.53%, and closed at $41.03.

According to BUSINESS WIRE, The Fresh Market, Inc. (TFM), a growing specialty grocery retailer, declared unaudited sales and earnings results for its thirteen-week fourth quarter and fiscal year ended January 25, 2015.

Fiscal Fourth Quarter Financial Overview:

• Diluted earnings per share under U.S. generally accepted accounting principles (“GAAP”) in the fourth quarter of fiscal 2014 were $0.42 per share, contrast to $0.04 per share in the fourth quarter of fiscal 2013. Fourth quarter fiscal 2014 results comprise asset impairment, leadership change, and net store closure charges of $0.13, and fourth quarter fiscal 2013 results comprise impairment charges for certain real estate and store related assets of $0.35.
• Adjusted diluted earnings per share were $0.55, not including asset impairment, leadership change, and net store closure charges of $0.13, for the fourth quarter of fiscal 2014, contrast to adjusted diluted earnings per share of $0.39, not including impairment charges of $0.35, for the fourth quarter of fiscal 2013. Adjusted diluted earnings per share is a non-GAAP financial measure. The plans comprised of in this press release comprise a reconciliation of this and other non-GAAP financial measures referenced to their comparable GAAP financial measures.
• GAAP net revenue in the fourth quarter of fiscal 2014 was $20.2 million, contrast to $2.0 million in the fourth quarter of fiscal 2013.
• Adjusted EBITDA in the fourth quarter of fiscal 2014 was $60.8 million, contrast to $47.0 million in the fourth quarter of fiscal 2013, an raise of 29.3%. Adjusted EBITDA is a non-GAAP financial measure.
• Net sales for the fourth quarter of fiscal 2014 raised 12.8% to $480.5 million and comparable store sales raised 3.0% to $412.3 million from the fourth quarter of fiscal 2013.
• Gross profit for the fourth quarter of fiscal 2014 raised 15.4%, or $22.0 million, to $164.7 million, contrast to the fourth quarter of fiscal 2013. Gross margin raised 80 basis points to 34.3%, contrast to 33.5% in the fourth quarter of the preceding fiscal year.
• The Corporation generated $44.8 million in cash flow from operations during the fourth quarter of fiscal 2014, contrast to $35.8 million in the fourth quarter of the preceding fiscal year. The resulting cash balance was $48.5 million as of January 25, 2015.

Founded in 1982, The Fresh Market, Inc. is a specialty grocery retailer focused on providing high-quality products in a unique and inviting atmosphere with a high level of customer service. As of March 5, 2015, the Corporation operates 171 stores in 28 states across the United States.

Catalyst Pharmaceutical Partners Inc. (CPRX) enhanced 3.22%, and closed at $4.17, hitting new 52-week high of $4.24.

According to GLOBE NEWSWIRE, Catalyst Pharmaceutical Partners Inc. (CPRX), a biopharmaceutical corporation focused on developing and commercializing innovative therapies for people with rare debilitating diseases, declared that the U.S. Food and Drug Administration (FDA) has granted the corporation orphan drug designation for Firdapse(TM) for treatment of patients with Congenital Myasthenic Syndromes (CMS).

CMS is a rare neuromuscular disease comprising a spectrum of genetic defects and is characterized by fatigable weakness of skeletal muscles with onset at or shortly after birth or early childhood; in rare cases symptoms may not manifest themselves until later in childhood. The severity and course of the disease are variable, ranging from minor symptoms to progressive disabling weakness; symptoms may be mild, but sudden severe exacerbations of weakness or even sudden episodes of respiratory insufficiency also occur.

“We are happy with the FDA’s decision to grant Orphan Drug designation to Firdapse(TM) for CMS as it provides Catalyst with a number of benefits through development and commercialization,” noted Patrick J. McEnany, Chief Executive Officer of Catalyst. He continued, “CMS is a disabling and frequently severe disease with few effective treatment options. The orphan drug designation recognizes the noteworthy unmet medical need that exists among individuals living with this disease.”

Catalyst Pharmaceuticals is a biopharmaceutical corporation focused on developing and commercializing innovative therapies for people with rare debilitating diseases, counting Lambert-Eaton Myasthenic Syndrome (LEMS), congenital myasthenic syndrome (CMS), infantile spasms, and Tourette Syndrome.

InspireMD, Inc. (NYSEMKT:NSPR), rose 3.20%, and closed at $0.29.

According to PRNewswire, InspireMD, Inc. (NSPR), a leader in embolic protection systems, declared that it will release its full financial results for the fourth quarter and year end December 31, 2014 on Thursday, March 12th after market close, followed by a conference call at 4:30 p.m. ET to review its financial results and business outlook.

InspireMD seeks to utilize its proprietary MGuard™ with MicroNet™ technology to make its products the industry standard for embolic protection and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization, no reflow and major adverse cardiac events.